appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
News & Opinions
Jenburkt Pharmaceuticals standalone net profit rises 38.18% in the June 2024 quarter
2 months ago•Business Standard
Pharma stock declares ₹702 share buyback at a premium of 13%
1 year ago•Livemint
Dividend paying pharma stock to consider share buyback
1 year ago•Livemint
Jenburkt Pharmaceuticals standalone net profit rises 40.56% in the September 2021 quarter
2 years ago•Business Standard
Jenburkt Pharmaceuticals standalone net profit declines 16.02% in the March 2021 quarter
3 years ago•Business Standard
Stocks in news: ITC, Infosys, PVR, MTAR Tech, SBI, Panacea Biotec and Radico Khaitan
3 years ago•Economic Times
Jenburkt Pharmaceuticals standalone net profit rises 28.23% in the December 2020 quarter
3 years ago•Business Standard